Skip to main content

Hereditary Cancer in Clinical Practice

Ausgabe 1/2009

Inhalt (17 Artikel)

Open Access Editorial

Hereditary Cancer in Clinical Practice transfers to BioMed Central

Jan Lubiński, Rolf H Sijmons, Rodney J Scott

Open Access Case report

Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing

Anna P Sokolenko, Dmitry A Voskresenskiy, Aglaya G Iyevleva, Elena M Bit-Sava, Nadezhda I Gutkina, Maxim S Anisimenko, Nathalia Yu Sherina, Nathalia V Mitiushkina, Yulia M Ulibina, Olga S Yatsuk, Olga A Zaitseva, Evgeny N Suspitsin, Alexandr V Togo, Valery A Pospelov, Sergey P Kovalenko, Vladimir F Semiglazov, Evgeny N Imyanitov

Open Access Research

Genetic variants in MUTYH are not associated with endometrial cancer risk

Katie A Ashton, Anthony Proietto, Geoffrey Otton, Ian Symonds, Rodney J Scott

Open Access Research

The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype

Marielle WG Ruijs, Annegien Broeks, Fred H Menko, Margreet GEM Ausems, Anja Wagner, Rogier Oldenburg, Hanne Meijers-Heijboer, Laura J van't Veer, Senno Verhoef

Open Access Research

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients

Evgeny N Suspitsin, Nathalia Yu Sherina, Daria N Ponomariova, Anna P Sokolenko, Aglaya G Iyevleva, Tatyana V Gorodnova, Olga A Zaitseva, Olga S Yatsuk, Alexandr V Togo, Nathalia N Tkachenko, Grigory A Shiyanov, Oksana S Lobeiko, Nadezhda Yu Krylova, Dmitry E Matsko, Sergey Ya Maximov, Adel F Urmancheyeva, Nathalia V Porhanova, Evgeny N Imyanitov

Open Access Research

Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy

Murly BM Tan, Eveline MA Bleiker, Marian BE Menke-Pluymers, Arthur R Van Gool, Silvia van Dooren, Bert N Van Geel, Madeleine MA Tilanus-Linthorst, Karina CM Bartels, Jan GM Klijn, Cecile TM Brekelmans, Caroline Seynaeve

Open Access Research

Survival in Norwegian BRCA1 mutation carriers with breast cancer

Anne Irene Hagen, Steinar Tretli, Lovise Mæhle, Jaran Apold, Nina Vedå, Pål Møller

Open Access Research

Australian clinicians and chemoprevention for women at high familial risk for breast cancer

Louise A Keogh, John L Hopper, Doreen Rosenthal, Kelly-Anne Phillips

Open Access Letter to the Editor

Early-onset breast cancer in a Lebanese family with Lynch syndrome due to MSH2 gene mutation

Riad Akoum, Albert Ghaoui, Emile Brihi, Maroun Ghabash, Nicolas Hajjar

Open Access Research

Factors associated with testicular self-examination among unaffected men from multiple-case testicular cancer families

Susan T Vadaparampil, Richard P Moser, Jennifer Loud, June A Peters, Mark H Greene, Larissa Korde

Open Access Case report

Unusual presentation of Lynch Syndrome

Veronica PCC Yu, Marco Novelli, Stewart J Payne, Sam Fisher, Rebecca A Barnetson, Ian M Frayling, Ann Barrett, David Goudie, Audrey Ardern-Jones, Ros Eeles, Susan Shanley

Open Access Research

Molecular genetics analysis of hereditary breast and ovarian cancer patients in India

Nagasamy Soumittra, Balaiah Meenakumari, Tithi Parija, Veluswami Sridevi, Karunakaran N Nancy, Rajaraman Swaminathan, Kamalalayam R Rajalekshmy, Urmila Majhi, Thangarajan Rajkumar

Open Access Research

Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario

Yun-Hee Choi, Michelle Cotterchio, Gail McKeown-Eyssen, Monga Neerav, Bharati Bapat, Kevin Boyd, Steven Gallinger, John McLaughlin, Melyssa Aronson, Laurent Briollais

Open Access Research

Risk perception after genetic counseling in patients with increased risk of cancer

Johanna Rantala, Ulla Platten, Gunilla Lindgren, Bo Nilsson, Brita Arver, Annika Lindblom, Yvonne Brandberg

Open Access Research

Penetrance of HNPCC-related cancers in a retrolective cohort of 12 large Newfoundland families carrying a MSH2 founder mutation: an evaluation using modified segregation models

Karen A Kopciuk, Yun-Hee Choi, Elena Parkhomenko, Patrick Parfrey, John McLaughlin, Jane Green, Laurent Briollais

Open Access Research

Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management

Dewkoemar Ramsoekh, Anja Wagner, Monique E van Leerdam, Dennis Dooijes, Carli MJ Tops, Ewout W Steyerberg, Ernst J Kuipers

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.